NCT05489679

A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Terminated Phase 1 Last updated 25 January 2024

What this trial tests

Phase 1 trial testing AC682 in Breast Cancer in 6 participants. Terminated before completion.

Timeline

1 October 2022

Primary endpoint
28 September 2023

28 September 2023

Quick facts

Lead sponsor	Accutar Biotechnology Inc
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	1 October 2022
Primary completion	28 September 2023
Estimated completion	28 September 2023
Sites	3 locations across China

Drugs / interventions tested

• AC682 — full drug profile →

Conditions studied

• Breast Cancer — all drugs for Breast Cancer →

Sponsor

Accutar Biotechnology Inc — full company profile →

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This clinical trial is evaluating AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to:

1. To evaluate the safety and tolerability of AC682
2. To evaluate the pharmacokinetic of AC682
3. To evaluate the preliminary anti-tumor activity of AC682

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Targeted protein degradation: advances in drug discovery and clinical practice.
   Zhong G, Chang X, Xie W, Zhou X. · · 2024 · cited 112× · PMID 39500878 · DOI 10.1038/s41392-024-02004-x
2. Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
   Li R, Liu M, Yang Z, Li J, et al · · 2022 · cited 45× · PMID 36557960 · DOI 10.3390/molecules27248828
3. Cereblon-Recruiting PROTACs: Will New Drugs Have to Face Old Challenges?
   Cieślak M, Słowianek M. · · 2023 · cited 31× · PMID 36986673 · DOI 10.3390/pharmaceutics15030812
4. NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders.
   Ma Z, Zhou J. · · 2025 · cited 28× · PMID 40702893 · DOI 10.1021/acs.jmedchem.5c01818
5. RIPTACs: A groundbreaking approach to drug discovery.
   Ma Z, Bolinger AA, Zhou J. · · 2023 · cited 20× · PMID 37734702 · DOI 10.1016/j.drudis.2023.103774
6. Targeted Protein Degradation: Clinical Advances in the Field of Oncology.
   Salama AKAA, Trkulja MV, Casanova E, Uras IZ. · · 2022 · cited 19× · PMID 36499765 · DOI 10.3390/ijms232315440
7. The future of pharmaceuticals: Artificial intelligence in drug discovery and development.
   Fu C, Chen Q. · · 2025 · cited 18× · PMID 40893437 · DOI 10.1016/j.jpha.2025.101248
8. New generation estrogen receptor-targeted agents in breast cancer: present situation and future prospectives.
   Min J, Liu X, Peng R, Chen CC, et al · · 2024 · cited 16× · PMID 39373009 · DOI 10.15212/amm-2024-0006